Q-omics provides the consensus-scored TSPAN10 profile across patient tissues and cancer cell-line models. TSPAN10 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TSPAN10 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, TSPAN10 RNA expression shows 14,121 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where TSPAN10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN10 survival associations across molecular data types. TSPAN10 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN10 RNA expression–survival associations across cancer types. High TSPAN10 expression shows unfavorable associations in UVM, PAAD, COAD and KIRC, but favorable associations in BRCA and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TSPAN10 RNA expression.
This table summarizes TSPAN10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TSPAN10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN10 shows higher tumor expression in HNSC, KIRP, LIHC, LUAD, LUSC and UCEC. The HNSC box plot shows higher TSPAN10 RNA expression in tumor versus normal tissue (log2 FC = +2.568, t-test p < 0.001).
This table shows molecular features associated with TSPAN10 in patient tissues and cancer cell lines. In patient samples, TSPAN10 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SKIN.
